Viridian Therapeutics Inc
NASDAQ:VRDN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.6
25.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Viridian Therapeutics Inc
Wall Street
Price Targets
VRDN Price Targets Summary
Viridian Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
VRDN
is 40.35 USD
with a low forecast of 22.22 USD and a high forecast of 64.05 USD.
VRDN Last Price Targets
Viridian Therapeutics Inc
The latest public price target was made on Sep 13, 2024 by
Gregory Renza
from
RBC Capital
,
who expects
VRDN
stock to
rise by 96%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Gregory Renza
RBC Capital
|
44
USD
Upside 96% |
2 months ago
Sep 13, 2024
|
Viridian Therapeutics price target raised to $44 from $35 at RBC Capital
TheFly
|
Serge Belanger
Needham
|
38
USD
Upside 69% |
2 months ago
Sep 11, 2024
|
Viridian Therapeutic (VRDN) PT Raised to $38 at Needham
StreetInsider
|
|
Kalpit Patel
B.Riley Financial
|
22
USD
Downside 2% |
2 months ago
Sep 11, 2024
|
Viridian Therapeutic (VRDN) PT Raised to $22 at B.Riley
StreetInsider
|
|
Julian Harrison
BTIG
|
56
USD
Upside 150% |
2 months ago
Sep 10, 2024
|
Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG
StreetInsider
|
Alex Thompson
Stifel Nicolaus
|
40
USD
Upside 78% |
2 months ago
Sep 10, 2024
|
Viridian Therapeutics price target raised to $40 from $33 at Stifel
TheFly
|
Richard Law
Goldman Sachs
|
25
USD
Upside 11% |
2 months ago
Aug 14, 2024
|
Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
StreetInsider
|
|
Gregory Renza
RBC Capital
|
35
USD
Upside 56% |
5 months ago
Jun 11, 2024
|
RBC Capital Reiterates Outperform Rating on Viridian Therapeutic (VRDN)
StreetInsider
|
|
Julian Harrison
BTIG
|
46
USD
Upside 105% |
5 months ago
Jun 11, 2024
|
BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)
StreetInsider
|
Andy Chen
Wolfe Research
|
29
USD
Upside 29% |
5 months ago
Jun 10, 2024
|
Viridian Therapeutics initiated with an Outperform at Wolfe Research
TheFly
|
|
Richard Law
Goldman Sachs
|
23
USD
Upside 3% |
5 months ago
Jun 6, 2024
|
Viridian Therapeutics initiated with a Buy at Goldman Sachs
TheFly
|
Leland Gershell
Oppenheimer
|
31
USD
Upside 38% |
6 months ago
May 9, 2024
|
Viridian Therapeutic (VRDN) PT Lowered to $31 at Oppenheimer
StreetInsider
|
|
Douglas Tsao
H.C. Wainwright
|
27
USD
Upside 20% |
6 months ago
May 9, 2024
|
Viridian Therapeutic (VRDN) PT Lowered to $27 at H.C. Wainwright
StreetInsider
|
|
Kalpit Patel
B.Riley Financial
|
20
USD
Downside 11% |
6 months ago
May 9, 2024
|
B.Riley Downgrades Viridian Therapeutic (VRDN) to Neutral
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is VRDN's stock price target?
Price Target
40.35
USD
According to Wall Street analysts, the average 1-year price target for
VRDN
is 40.35 USD
with a low forecast of 22.22 USD and a high forecast of 64.05 USD.
What is Viridian Therapeutics Inc's Revenue forecast?
Projected CAGR
415%
For the last 8 years the
compound annual growth rate for
Viridian Therapeutics Inc's revenue is
-23%.
The projected
CAGR
for the next 3 years is
415%.
You don't have any saved screeners yet
